TG Therapeutics Signs Ex-US Commercialization Agreement with Neuraxpharm for Briumvi (ublituximab-xiiy)
Shots:
- TG will receive $140M up front, $12.5M upon launch in the first EU country, ~$492.5M upon achievement of launch and commercial milestones along with royalties on net product sales ~30%
- Neuraxpharm to get an exclusive right to commercialize Briumvi for RMS in the EU & certain other territories outside the US excl. Canada & Mexico which are retained by TG & certain Asian countries. TG holds an option to buy back all commercial rights over the next 2yrs. if TG is acquired
- The centralized marketing authorization is valid in all EU Member States, Iceland, Norway & Liechtenstein. Briumvi, the first anti-CD20 mAb was approved in the US & EU for adult patients with RMS that can be administered in a 1hr. infusion, twice a year following the starting dose
Ref: Globenewswire | Image: TG Therapeutics
Related News:- TG Therapeutics’ Briumvi (ublituximab-xiiy) Receives EC’s Approval for the Treatment of Relapsing Forms of Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
